Zymeworks Inc. (ZYME) stock plunged 5.46% in the after-hours trading session on Wednesday after reporting a wider-than-expected loss and lower-than-anticipated revenue for the fourth quarter.
The biopharmaceutical company reported a net loss of $0.31 per diluted share for the quarter, significantly missing analysts' expectations of a $0.03 loss. The company's revenue also fell short, coming in at $31 million compared to the estimated $45.2 million.
The disappointing results likely contributed to the sharp decline in Zymeworks' stock price in the after-hours market, as investors reacted negatively to the company's performance. The broader market outlook and future growth prospects may also have played a role in the sell-off.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。